Sanofi Promotes Heart Disease Management in Mexico
Sanofi highlights the importance of managing heart diseases in Mexico, where they were a significant cause of death in 2020. The company offers solutions for prevention and treatment.
Pharmaceutical company Sanofi has underscored the importance of managing heart diseases in Mexico. According to data, heart conditions were a significant cause of death in the country from January to August 2020, accounting for 20.8 percent of all fatalities.
For over 50 years, Sanofi has provided solutions for the prevention and treatment of heart attacks, hypertension, and thrombosis in Mexico. The company aims to advance public health by offering information and treatment options.
As part of its commitment, Sanofi has introduced the "Decalogue for Heart Control," a set of ten simple recommendations for individuals with cardiovascular diseases and those at risk. These guidelines are intended to support patients in their treatment journey.
Heart diseases, COVID-19, and diabetes mellitus were identified as the leading causes of death in Mexico during 2020, according to INEGI. Sanofi continues its dedication to promoting heart health within the country.